MENU
+Compare
JANX
Stock ticker: NASDAQ
AS OF
Jul 21 closing price
Price
$26.08
Change
-$0.32 (-1.21%)
Capitalization
1.54B

JANX Janux Therapeutics Forecast, Technical & Fundamental Analysis

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JANX with price predictions
Jul 21, 2025

Momentum Indicator for JANX turns positive, indicating new upward trend

JANX saw its Momentum Indicator move above the 0 level on July 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 70 similar instances where the indicator turned positive. In of the 70 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for JANX just turned positive on July 01, 2025. Looking at past instances where JANX's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

JANX moved above its 50-day moving average on July 09, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for JANX crossed bullishly above the 50-day moving average on July 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JANX advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 142 cases where JANX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for JANX moved out of overbought territory on July 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where JANX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JANX broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). JANX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (158.730) is also within normal values, averaging (274.844).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly better than average price growth. JANX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JANX is expected to report earnings to rise 21.37% to -46 cents per share on August 12

Janux Therapeutics JANX Stock Earnings Reports
Q2'25
Est.
$-0.46
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
Q2'24
Beat
by $0.20
The last earnings report on May 09 showed earnings per share of -37 cents, missing the estimate of -37 cents. With 724.73K shares outstanding, the current market capitalization sits at 1.54B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDOEX11.30N/A
N/A
Morgan Stanley Developing Opportunity I
FPCSX43.42N/A
N/A
FPA Crescent Supra Institutional
INUTX39.58-0.04
-0.10%
Columbia Dividend Opportunity A
PCLVX21.98-0.08
-0.36%
PACE Large Co Value Equity P
PPIMX8.05-0.05
-0.62%
Principal MidCap Growth III Inst

JANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with CRNX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
-1.21%
CRNX - JANX
39%
Loosely correlated
-0.51%
IDYA - JANX
39%
Loosely correlated
+1.02%
SYRE - JANX
38%
Loosely correlated
+0.37%
APGE - JANX
37%
Loosely correlated
-0.51%
KYMR - JANX
37%
Loosely correlated
-2.25%
More